DT2216 Earns Fast Track Designation for PTCL, CTCL
Photo by National Cancer Institute on Unsplash

DT2216 Earns Fast Track Designation for PTCL, CTCL

On April 6, 2022, biotechnology company Dialectic Therapeutics announced via press release that its therapeutic candidate DT2216, designed for relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL) or peripheral T-cell…

Continue Reading DT2216 Earns Fast Track Designation for PTCL, CTCL
I/ONTAK Shows Benefit for CTCL
https://pixabay.com/photos/hospital-infusion-hand-association-834157/

I/ONTAK Shows Benefit for CTCL

In a Phase 3 clinical trial, researchers evaluated I/ONTAK (also known as E7777) as a potential therapeutic option for persistent or recurrent cutaneous T-cell lymphoma (CTCL). According to Targeted Oncology,…

Continue Reading I/ONTAK Shows Benefit for CTCL

Cutaneous T Cell Lymphoma Outcomes Improved with Investigative BV Therapy in Phase 3 Clinical Trial

A study recently published in the journal Blood Advances has demonstrated that brentuximab vedotin (BV) treatment leads to improved outcomes for primary cutaneous anapestic large-cell lymphoma (C-ALCL) and CD30-expressing mycosis fungoides (MF)…

Continue Reading Cutaneous T Cell Lymphoma Outcomes Improved with Investigative BV Therapy in Phase 3 Clinical Trial
Interim Data from this Cutaneous T-Cell Lymphoma Trial is Looking Promising
source: pixabay.com

Interim Data from this Cutaneous T-Cell Lymphoma Trial is Looking Promising

According to a story from BioSpace, the biopharmaceutical company Bioniz Therapeutics, Inc., has recently announced the release of interim results from its phase 1/2 clinical trial. This trial is investigating…

Continue Reading Interim Data from this Cutaneous T-Cell Lymphoma Trial is Looking Promising
Company Releases Early Clinical Data For Experimental Blood Cancer Drug
SarahMarciano / Pixabay

Company Releases Early Clinical Data For Experimental Blood Cancer Drug

According to a story from pm360online.com, the biopharmaceutical company miRagen Therapeutics, Inc., recently presented Phase I clinical trial data regarding the company's experimental drug cobomarsen. This data was presented at…

Continue Reading Company Releases Early Clinical Data For Experimental Blood Cancer Drug
A New Drug May Be Coming to the Market for Cutaneous T-cell Lymphoma
https://pixabay.com/en/youth-active-jump-happy-sunrise-570881/

A New Drug May Be Coming to the Market for Cutaneous T-cell Lymphoma

A phase 3 clinical trial has produced positive results for cutaneous T-cell lymphoma (CTCL) patients. The drug tested is called brentuximab vedotin (Adcetris). Specifically, the drug was created to treat…

Continue Reading A New Drug May Be Coming to the Market for Cutaneous T-cell Lymphoma